Research

Tennessee Retina is an active participant in many national research trials. The efforts of our physicians and patients have led to the approval of many treatments now considered to be the standard of care, and our continuing involvement in clinical research offers access to new and potentially superior treatments to patients with sight-threatening conditions.

As with all patients, our clinical trial patients are very important to us, and we provide them with exceptional care and attention. Please contact your current eyecare provider to see if you may qualify for one of our studies, or contact one of our Clinical Trial staff members with any questions at (615) 983-6000.

Diabetes in the Eyes

MYLAN/INSIGHT (Enrolling)
NCT03610646  Clinical Trials.gov
A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema

RHINE GR40398 (Active, Not Recruiting)
NCT03622593  Clinical Trials.gov
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Diabetic Macular Edema

PAGODA (Enrolling)
NCT04108156  Clinical Trials.gov
This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic Macular Edema (DME) when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W).

PAVILION (Enrolling)
NCT listing coming soon on  Clinical Trials.gov

 

Age-Related Macular Degeration (AMD)

PANDA (Active, Not Recruiting)
NCT03577899 Clinical Trials.gov
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration.

TENAYA (Active, Not Recruiting)
NCT03823287 Clinical Trials.gov
A Phase III, multicenter, randomized, single-masked, active comparator controlled study to evaluate RO6867461 in patients with Neovascular Age-Related Macular Degeneration.

GALLEGO (Enrolling)
NCT03972709 Clinical Trials.gov
A Phase II, multicenter, randomized, single-masked, sham injection-controlled study of the safety, tolerability, and evidence of activity of intravitreal injection of RO7171009 in patients with Geographic Atrophy secondary to age-related macular degeneration

SPIAM (Enrolling, Ending Soon)
NCT03891875 Clinical Trials.gov
A Phase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Elamipretide Solution in Subjects with Age-Related Macular Degeneration with Geographic Atrophy

OPTIC (Adverum) (Enrolling)
NCT03748784  Clinical Trials.gov
An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration

ASTELLAS (Enrolling)
NCT03178149  Clinical Trials.gov
A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration

ARCHWAY - GR40548 (Active, Not Recruiting)
NCT03677934  Clinical Trials.gov
Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

TRISTAR (Not Active, Not Recruiting)
NCT03468296  Clinical Trials.gov
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

PORTAL - LADDER EXT GR40549 (Active, Not Recruiting)
NCT03683251  Clinical Trials.gov
A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

DAZZLE/KODIAK (Enrolling)
NCT04049266  Clinical Trials.gov
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of KSI-301 administered at 12, 16 and 20 weeks intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with treatment-naïve neovascular (wet) age-related macular degeneration (nAMD).

DERBY (Enrolling, Ending Soon)
NCT03525600  Clinical Trials.gov
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.

OAKS (Enrolling, Ending Soon)
NCT03525613  Clinical Trials.gov
This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.

 

Vein Occlusion

SCORE 2 (Active, Not Recruiting)
NCT01969708  Clinical Trials.gov
Study of Comparative Treatments for Retinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.

RAVEN (Enrolling)
NCT03810313 Clinical Trials.gov
An Eighteen-Month, Two-Arm, Randomized, Double- Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion